Ascendis Pharma A/s Share Price (NASDAQ: ASND)

$194.12

▲

0.04

(0.02%)

Live

Last updated on August 19, 2025 at 11:41 PM IST

$₹

Check the interactive Ascendis Pharma A/s Stock chart to analyse performance

Ascendis Pharma A/s stock performance

as on August 19, 2025 at 11:41 PM IST

Today's Low:$193.01
Today's High:$194.45
$194.12
0.57%
Downside
Day's Volatility :0.74%
Upside
0.17%
52 Weeks Low:$111.09
52 Weeks High:$199.99
$194.12
42.77%
Downside
52 Weeks Volatility :44.45%
Upside
2.94%

Ascendis Pharma A/s Stock Returns

Period	Ascendis Pharma A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	20.24%	1.1%	0.0%
6 Months	24.38%	-7.2%	0.0%
1 Year	40.96%	-11.6%	0.0%
3 Years	116.82%	2.2%	-9.6%

Ascendis Pharma A/s Key Stats

Check Ascendis Pharma A/s key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$194.08
Open	$195.52
Today's High	$195.86
Today's Low	$193.01
Market Capitalization	$12.0B
Today's Volume	$587.8K
52 Week High	$199.99
52 Week Low	$111.09
Revenue TTM	$490.7M
EBITDA	$-248.6M
Earnings Per Share (EPS)	$-5.31
Profit Margin	-55.25%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-818.43%

Stock Returns calculator for Ascendis Pharma A/s Stock including INR - Dollar returns

The Ascendis Pharma A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ascendis Pharma A/s investment value today

Current value as on today

₹1,44,474

Returns

₹44,474

(+44.47%)

Returns from Ascendis Pharma A/s Stock

₹40,850 (+40.85%)

Dollar Returns*

₹3,624 (+3.62%)

Indian investors sentiment towards Ascendis Pharma A/s Stock

-8%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Search interest for Ascendis Pharma A/s Stock from India on INDmoney has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Ascendis Pharma A/s

Name
Holdings %
Name
Holdings %
RA Capital Management, LLC
17.01%
Westfield Capital Management Company, L.P.
9.02%
venBio Select Advisor LLC
8.24%
FMR Inc
7.73%
HHG PLC
7.32%
Artisan Partners Limited Partnership
6.60%

Analyst Recommendation on Ascendis Pharma A/s Stock

Rating

Trend

Buy

80%Buy

20%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Ascendis Pharma A/s(by analysts ranked 0 to 5 stars)

Ascendis Pharma A/s Share Price Target

What analysts predicted

Upside of 29.72%

Target:

$251.82

Current:

$194.12

Ascendis Pharma A/s share price target is $251.82, a slight Upside of 29.72% compared to current price of $194.12 as per analysts' prediction.

Ascendis Pharma A/s Stock Insights

Price Movement
In the last 1 month, ASND stock has moved up by 14.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 100.95M → 158.04M (in $), with an average increase of 36.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -94.62M → -38.85M (in $), with an average increase of 143.5% per quarter
ASND vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.4% return, outperforming this stock by 25.4%
ASND vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 1.7%
Price to Sales
ForASND every $1 of sales, investors are willing to pay $23.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.0 for every $1 of sales.

Ascendis Pharma A/s Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$14.9M	↑ 26.41%
Net Income	$-242.3M	↑ 67.58%
Net Profit Margin	-1.6K%	↓ 400.5%

	FY20	Y/Y Change
Revenue	$8.5M	↓ 48.01%
Net Income	$-509.6M	↑ 92.17%
Net Profit Margin	-6.0K%	↓ 4395.5%

	FY21	Y/Y Change
Revenue	$8.8M	↑ 11.87%
Net Income	$-433.6M	↓ 8.44%
Net Profit Margin	-4.9K%	↑ 1093.97%

	FY22	Y/Y Change
Revenue	$54.2M	↑ 557.93%
Net Income	$-617.2M	↑ 52.04%
Net Profit Margin	-1.1K%	↑ 3791.93%

	FY23	Y/Y Change
Revenue	$291.0M	↑ 421.2%
Net Income	$-525.2M	↓ 17.45%
Net Profit Margin	-180.51%	↑ 959.12%

	FY24	Y/Y Change
Revenue	$380.5M	↑ 36.34%
Net Income	$-395.6M	↓ 21.47%
Net Profit Margin	-103.97%	↑ 76.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$104.2M	↓ 30.36%
Net Income	$-142.4M	↑ 50.83%
Net Profit Margin	-136.65%	↓ 73.56%

	Q2 FY24	Q/Q Change
Revenue	$36.0M	↓ 62.46%
Net Income	$-109.4M	↓ 16.53%
Net Profit Margin	-303.85%	↓ 167.2%

	Q3 FY24	Q/Q Change
Revenue	$57.8M	↑ 60.66%
Net Income	$-99.2M	↓ 9.31%
Net Profit Margin	-171.52%	↑ 132.33%

	Q4 FY24	Q/Q Change
Revenue	$182.0M	↑ 200.72%
Net Income	$-40.2M	↓ 61.22%
Net Profit Margin	-22.12%	↑ 149.4%

	Q1 FY25	Q/Q Change
Revenue	$101.0M	↓ 41.95%
Net Income	$-94.6M	↑ 145.98%
Net Profit Margin	-93.73%	↓ 71.61%

	Q2 FY25	Q/Q Change
Revenue	$158.0M	↑ 56.55%
Net Income	$-38.9M	↓ 58.94%
Net Profit Margin	-24.58%	↑ 69.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$14.9M	↑ 26.41%

	FY20	Y/Y Change
Profit	$8.5M	↓ 48.01%

	FY21	Y/Y Change
Profit	$4.8M	↓ 38.8%

	FY22	Y/Y Change
Profit	$41.3M	↑ 817.44%

	FY23	Y/Y Change
Profit	$242.5M	↑ 469.52%

	FY24	Y/Y Change
Profit	$334.1M	↑ 43.66%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$96.0M	↓ 25.3%

	Q2 FY24	Q/Q Change
Profit	$24.5M	↓ 72.22%

	Q3 FY24	Q/Q Change
Profit	$46.6M	↑ 90.08%

	Q4 FY24	Q/Q Change
Profit	$167.3M	↑ 242.88%

	Q1 FY25	Q/Q Change
Profit	$83.4M	↓ 47.82%

	Q2 FY25	Q/Q Change
Profit	$126.6M	↑ 51.73%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-195.5M	↑ 26.75%
Investing Cash Flow	$-5.7M	↑ 94.83%
Financing Cash Flow	$548.5M	↑ 142.83%

	FY20	Y/Y Change
Operating Cash Flow	$-330.3M	↑ 54.34%
Investing Cash Flow	$-354.2M	↑ 5544.49%
Financing Cash Flow	$733.0M	↑ 22.09%

	FY21	Y/Y Change
Operating Cash Flow	$-472.1M	↑ 53.8%
Investing Cash Flow	$-125.0M	↓ 62.03%
Financing Cash Flow	$397.2M	↓ 41.69%

	FY22	Y/Y Change
Operating Cash Flow	$-524.6M	↑ 18.69%
Investing Cash Flow	$65.3M	↓ 155.83%
Financing Cash Flow	$419.9M	↑ 12.92%

	FY23	Y/Y Change
Operating Cash Flow	$-509.8M	↓ 5.72%
Investing Cash Flow	$312.5M	↑ 364.06%
Financing Cash Flow	$146.5M	↓ 66.15%

	FY24	Y/Y Change
Operating Cash Flow	$-320.4M	↓ 34.48%
Investing Cash Flow	$7.2M	↓ 97.6%
Financing Cash Flow	$464.5M	↑ 230.57%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-110.4M	↑ 139.19%
Investing Cash Flow	$7.8M	↑ 7.58%
Financing Cash Flow	$20.0M	↓ 404.26%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-66.0M	↓ 39.65%
Investing Cash Flow	$654.2K	↓ 91.5%
Financing Cash Flow	$-2.6M	↓ 113.33%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-62.3M	↓ 8.44%
Investing Cash Flow	$-558.5K	↓ 182.73%
Financing Cash Flow	$475.1M	↓ 17528.68%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-91.2M	↑ 55.31%
Investing Cash Flow	$-401.8K	↓ 23.66%
Financing Cash Flow	$91.0K	↓ 99.98%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-15.5M	↓ 83.58%
Investing Cash Flow	$-760.2K	↑ 83.07%
Financing Cash Flow	$-19.5M	↓ 20817.24%

Ascendis Pharma A/s Technicals Summary

Sell

Neutral

Buy

Ascendis Pharma A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ascendis Pharma A/s Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ascendis Pharma A/s	15.62%	24.38%	40.96%	116.82%	35.89%
Regeneron Pharmaceuticals, Inc.	5.3%	-15.53%	-52.01%	-6.15%	-6.88%
Beone Medicines Ltd	9.32%	34.03%	65.78%	84.48%	35.61%
Vertex Pharmaceuticals Incorporated	-14.97%	-15.63%	-20.12%	32.68%	43.64%
Alnylam Pharmaceuticals, Inc.	42.53%	82.74%	66.44%	109.65%	235.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ascendis Pharma A/s	NA	NA	NA	-2.39	-8.18	-0.17	NA	-3.1
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ascendis Pharma A/s	Buy	$12.0B	35.89%	NA	-55.25%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-6.88%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	35.61%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	43.64%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.02%	NA	-12.96%

Ascendis Pharma A/s Dividend announcements

Ascendis Pharma A/s Earnings
Ascendis Pharma A/s’s price-to-earnings ratio stands at None

About Ascendis Pharma A/s

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Organization	Ascendis Pharma A/s
Employees	1017
CEO	Mr. Jan Moller Mikkelsen
Industry	Health Technology

Key Management of Ascendis Pharma A/s

Name	Title
Mr. Jan Moller Mikkelsen	President, CEO, Member of Executive Board & Executive Director
Mr. Scott T. Smith	CFO, Executive VP & Member of Executive Board
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg	Executive VP, Chief Administrative Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M.	Executive VP, Chief Legal Officer & Member of the Executive Board
Mr. Mads Bodenhoff	Senior VP, Head of Finance & Principal Accounting Officer
Mr. Flemming Steen Jensen	Executive Vice President of Product Supply & Quality
Dr. Kennett Sprogoe Ph.D.	Executive VP and Head of Research & Product Development
Dr. Stina Singel M.D., Ph.D.	Executive VP & Head of Clinical Development for Oncology
Mr. Joseph Kelly	Head of U.S. Commercial of Endocrinology
Ms. Sherrie Glass	Chief Business Officer

Important FAQs about investing in ASND Stock from India :

What is Ascendis Pharma A/s share price today?

Ascendis Pharma A/s share price today is $194.12 as on August 19, 2025 at 11:41 PM IST. Ascendis Pharma A/s share today touched a day high of $194.45 and a low of $193.01.

What is the 52 week high and 52 week low for Ascendis Pharma A/s share?

Ascendis Pharma A/s share touched a 52 week high of $199.99 and a 52 week low of $111.09. Ascendis Pharma A/s stock price today i.e. August 19, 2025 at 11:41 PM IST is trending at $194.12, lower by 2.94% versus the 52 week high.

How to invest in Ascendis Pharma A/s Stock (ASND) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ascendis Pharma A/s on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ascendis Pharma A/s Shares that will get you 0.0077 shares as per Ascendis Pharma A/s share price of $194.12 per share as on August 19, 2025 at 11:41 PM IST.

What is the minimum amount required to buy Ascendis Pharma A/s Stock (ASND) from India?

Indian investors can start investing in Ascendis Pharma A/s (ASND) shares with as little as ₹86.938 or $1 (as of August 19, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹869.38 in Ascendis Pharma A/s stock (as per the Rupee-Dollar exchange rate as on August 19, 2025). Based on Ascendis Pharma A/s share’s latest price of $194.12 as on August 19, 2025 at 11:41 PM IST, you will get 0.0515 shares of Ascendis Pharma A/s. Learn more about fractional shares .

What are the returns that Ascendis Pharma A/s has given to Indian investors in the last 5 years?

Ascendis Pharma A/s stock has given 35.89% share price returns and 16.15% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?